Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
NextCure Inc
NASDAQ NXTC
Data sourced from
and
and
NextCure Inc Short-Term Investments for the Trailing 12 Months (TTM) ending March 31, 2024: USD 77.64 M
NextCure Inc Short-Term Investments is USD 77.64 M for the Trailing 12 Months (TTM) ending March 31, 2024, a -32.79% change year over year. Short-Term Investments are investments that are expected to be converted into cash within a year.
-
NextCure Inc Short-Term Investments for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 115.52 M, a -39.41% change year over year.
-
NextCure Inc Short-Term Investments for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 190.67 M, a -17.71% change year over year.
-
NextCure Inc Short-Term Investments for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 231.71 M, a -20.97% change year over year.
-
NextCure Inc Short-Term Investments for the Trailing 12 Months (TTM) ending March 31, 2020 was USD 293.19 M.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: NXTC
| CEO | Mr. Michael S. Richman MSBA |
| IPO Date | May 9, 2019 |
| Location | United States |
| Headquarters | 9000 Virginia Manor Road, Beltsville, MD, United States, 20705 |
| Employees | 82 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Key trends
StockViz Staff
September 20, 2024
Any question? Send us an email